Broadwood Partners Comments on STAAR Surgical Shareholders' Rejection of the Company's Proposed Sale to Alcon

Thanks Fellow Shareholders for Rejecting the Transaction

Reiterates Enthusiasm for the Company's Standalone Prospects

Looks Forward to Engaging with Board and Fellow Shareholders and Working Towards a Bright Future for STAAR

Broadwood Partners, L.P. and its affiliates ("Broadwood" or "we"), which together own 30.2% of the outstanding common stock of Staar Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), commented on the results of the Special Meeting of Shareholders (the "Special Meeting") that was held earlier today in connection with the proposed acquisition of STAAR by Alcon Inc. ("Alcon") (NYSE: ALC). Based on preliminary results, shareholders voted decisively to reject the proposed transaction.

Neal C. Bradsher, Broadwood Founder and President, said:

"We thank our fellow shareholders for their attention during this process and for rejecting the proposed acquisition of STAAR by Alcon at today's Special Meeting. We appreciate that so many shareholders recognize the value of STAAR and share our enthusiasm for the Company's bright future.

It is now time to focus on the road ahead. With its leading technology, strong financial position, privileged position in large markets, and clear path to growth and profit margin expansion in both the near term and the long term, STAAR's future is bright. As STAAR's largest shareholder, we are confident in the Company's standalone prospects and committed to helping STAAR realize its abundant potential for the benefit of all shareholders.

To that end, we are ready and willing to work collaboratively with the Board and our fellow shareholders to implement the necessary changes to enable effective oversight and execution on STAAR's opportunity to become a highly profitable and scaled enterprise.

STAAR now has a renewed opportunity to truly shine."

About Broadwood

Broadwood Partners, L.P. is managed by Broadwood Capital, Inc. Broadwood Capital is a private investment firm based in New York City. Neal Bradsher is the President of Broadwood Capital.

Investor Contacts
John Ferguson / Joseph Mills
Saratoga Proxy Consulting LLC
jferguson@saratogaproxy.com
jmills@saratogaproxy.com
(212) 257-1311
(888) 368-0379

Media Contacts
Scott Deveau / Jeremy Jacobs
August Strategic Communications
Broadwood@AugustCo.com
(323) 892-5562

News Provided by Business Wire via QuoteMedia

STAA
The Conversation (0)
Sidoti's Summer Small Cap Virtual Conference

Sidoti's Summer Small Cap Virtual Conference

Presentation Times and Weblinks Released for Over 70 Presenting Companies Wednesday and Thursday, June 15th-16th, 2022 Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day Summer Small Cap Virtual Conference taking place Wednesday and Thursday, June... Keep Reading...
Quantum Biopharma

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...

Interactive Chart

Latest Press Releases

Related News